TETaito Esaki

Taito Esaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Taito Esaki has a total of 156 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Anti-Epidermal Growth Factor Receptor Antibody Readministration in Chemorefractory Metastatic Colorectal Cancer

    by Tatsuhiro Kajitani, Akitaka Makiyama, Shuji Arita, Hozumi Shimokawa, Hisanobu Oda, Tsuyoshi Shirakawa, Eishi Baba, Taito Esaki

    Background/Aim: Readministration of anti-epidermal growth factor receptor (EGFR) antibody for metastatic colorectal cancer (mCRC) after disease progression remains to be determined. Patients and Methods: Readministration of anti-EGFR antibody in mCRC patients previously refractory to anti-EGFR antibody was prospectively observed. Results: A total of thirteen patients with a median age of 60-years old and an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, were enrolled. The median number of previous chemotherapies was 3 (range 2-5). Prior anti-EGFR antibody in combination with cytotoxic drugs was administered in 12 patients. Anti-EGFR antibody readministration regimens were cetuximab/panitumumab plus capecitabine/S-1 (seven patients), panitumumab plus FOLFOX (three patients), cetuximab plus irinotecan (two patients), and panitumumab monotherapy (one patient). Seven patients showed stable disease following readministration and six patients showed progressive disease. The median overall survival (OS) following readministration was 228 days and the median PFS was 102 days. Patients with intervals longer than 90 days between anti-EGFR therapies exhibited more favorable survival than those with intervals shorter than 90 days. Switching of anti-EGFR antibody between treatments was observed to contribute survival. Conclusion: Anti-EGFR antibody readministration could show a modest survival benefit in mCRC patients, with the length of therapy interval and switching of antibody being important contributory factors.


  • A phase II study (KSCC/HGCSG/CCOG/PerSeUS1501B) of trastuzumab plus S-1 and oxaliplatin for HER2-positive advanced gastric cancer.

    by Katsunori Shinozaki, Satoshi Yuki, Tomomi Kashiwada, Tetsuya Kusumoto, Masaaki Iwatsuki, Hironaga Satake, Kazuma Kobayashi, Taito Esaki, Yuichiro Nakashima, Nobuhide Kubo, et al.

    4059 Background: A combination of S-1 and cisplatin (SP) has been the standard regimen for advanced gastric cancer (AGC) in East Asia. The combination of S-1 and oxaliplatin (SOX100) was demonstrated to be non-inferior to SP in the randomized phase III study. The ToGA study demonstrated that trastuzumab (T-mab) combination therapies with cisplatin and fluoropyrimidines improved the overall survival of patients with HER2-positive AGC. This multicenter study is the first phase II trial to assess the efficacy and safety of T-mab in combination with S-1 and oxaliplatin (HER-SOX130) in HER2-positive AGC. Methods: Patients with HER2-positive AGC or recurrent gastric cancer defined to be IHC 3+ or IHC 2+/FISH positive received 80 mg/m2 S-1 per day orally on days 1–14, 130 mg/m2 oxaliplatin intravenously on day 1, and T-mab (8-mg/kg loading dose and 6 mg/kg thereafter) intravenously on day 1 of a 21-day cycle until one of the criteria for withdrawal of the study treatment occurred. The primary end-point was the response rate (RR). Adverse events were recorded based on the NCI-CTCAE Vers.4.0. The threshold response rate was defined as 50%, and the expected rate was set at 70%, with an 80% power and a 1-sided alpha value of 0.05. The calculated sample size was 37 patients. Results: For this study, 42 patients (median age, 66 years) were enrolled from June 2015 to May 2016. Three patients were excluded owing to ineligibility. Efficacy and safety analyses were conducted in the full analysis set of 39 patients. The proportion of patients with IHC 3+ was 87%. The confirmed RR assessed by the independent review committee was 82.1(32/39) % (95% confidence interval [CI]: 67.3–91.0), and the disease control rate was 87.2(34/39) % (95% CI: 73.3–94.4). The incidence rates of grade 3 or 4 adverse events were as follows: neutropenia, 12.8%; thrombocytopenia, 17.9%; anemia, 10.3%; sensory neuropathy, 5.1%; anorexia, 17.9%; diarrhea, 7.7%; and teary eyes, 2.6%. Conclusions: HER-SOX130 demonstrated encouraging efficacy with a favorable safety profile. The survival benefit of this regimen needs to be validated by conducting further follow-up of patients. Clinical trial information: 000017552.


  • Regorafenib (REG) versus trifluridine/tipiracil (TAS-102) as salvage-line in patients with metastatic colorectal cancer refractory to standard chemotherapies (REGOTAS): A propensity score analysis from a JSCCR multicenter observational study.

    by Shota Fukuoka, Toshikazu Moriwaki, Hiroya Taniguchi, Atsuo Takashima, Yosuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Taito Esaki, Akitaka Makiyama, Tadamichi Denda, et al.

    3540 Background: It is unclear which drug of REG or TAS-102 should be used earlier for the patients with metastatic colorectal cancer (mCRC) who have access to both drugs. This study investigated the comparison of the efficacy between REG and TAS-102 in patients with refractory to standard chemotherapies. Methods: The clinical data of patients who were treated with REG or TAS-102 among these drugs naive mCRC patients between Jun 2014 and Sep 2015 were retrospectively delivered from 24 institutions of Japanese Society for Cancer of the Colon and Rectum (JSCCR). The primary endpoint was overall survival (OS). Propensity score (PS) was calculated with a logistic regression, in which using baseline parameters were included. Two methods, adjusted and matched analysis, to take propensity score were used. The clinical outcomes were evaluated with Kaplan-Meier method and Cox models based on PS adjustment and matching. Results: Total of 589 patients were enrolled and 550 patients (223 patients in the REG group and 327 patients in the TAS-102 group) met criteria for inclusion in the analysis. The results from PS adjusted analyses showed that OS was similar between the two groups (HR of TAS-102 to REG, 0.96; 95% confidence interval, 0.78–1.18). There were also no statistically significant differences between two groups for progression-free survival (HR 0.94) and time to ECOG Performance status≥2 (HR 1.00), expect for time to treatment failure (HR 0.81; P = 0.025). In the subgroup analysis, REG showed favorable survival compared with TAS-102 in the age of < 65 years patients and unfavorable survival in ≥65 years patients (P for interaction = 0.012). In the PS matched sample (174 patients in each group), the clinical outcomes were similar to the results of the PS adjusted analysis. Conclusions: Although REG and TAS-102 showed a similar efficacy in mCRC patients with refractory to standard chemotherapies, the choice of the drug by age might affect the survival. Supported by JSCCR. Clinical trial information: UMIN000020416


  • Randomized phase II study of panitumumab (Pmab) + irinotecan (CPT-11) versus cetuximab (Cmab) + CPT-11 in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) after fluoropyrimidine (FU), CPT-11, and oxaliplatin (L-OHP) failure: WJOG6510G.

    by Naotoshi Sugimoto, Daisuke Sakai, Takao Tamura, Hiroki Hara, Tomohiro Nishina, Taito Esaki, Hiroyuki Okuda, Tadamichi Denda, Masahiro Tsuda, Taroh Satoh, et al.

    661 Background: Continuation of CPT-11 in combination with Cmab after CPT-11 failure has a survival benefit over Cmab alone. However, it is not clear whether CPT-11 with Pmab shows similar benefits. Methods: Pts with KRAS WT mCRC previously treated with FU-, L-OHP-, and CPT-11- based chemotherapies were randomized 1:1 to either Cmab + CPT-11(Cmab arm), or Pmab + CPT-11(Pmab arm). Primary objective was progression free survival (PFS), with an expected hazard ratio (HR) of 1.0 with non-inferiority margin of 1.3 (80% CI) using cox proportional hazards model. Median PFS with both arms were assumed to be 6.0 months. Secondary objectives were overall survival (OS), response rate (RR), disease control rate (DCR), and safety. Results: From December 2011 to September 2014, 121 pts were enrolled from 31 sites in Japan. Because 1 patient declined before treatment, totally, 120 (Cmab arm: 59, Pmab arm 61) pts were eligible for efficacy analysis. Baseline characteristics were well balanced between the two arms. 116 pts (96.7 %) were previously treated with bevacizumab. Efficacy results are shown in the table. The common grade 3 or 4 adverse events in Cmab/Pmab arm were leukopenia 19.0/3.3%, neutropenia 27.6/8.3%, hypomagnesaemia 6.9/16.7%, and rash 5.2/13.3 %, respectively. Conclusions: Non-inferiority of Pmab to Cmab in combination with CPT-11 was suggested for patients with KRAS WT mCRC previously treated with FU-, L-OHP-, and CPT-11- based chemotherapies, associated with favorable PFS and OS. Clinical trial information: UMIN000006643. [Table: see text]


  • Onset of neutropenia as an indicator of treatment response in the randomized phase II of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (Study J003-10040030).

    by Tomohiro Nishina, Takayuki Yoshino, Eiji Shinozaki, Kentaro Yamazaki, Yoshito Komatsu, Hideo Baba, Akihito Tsuji, Kensei Yamaguchi, Kei Muro, Naotoshi Sugimoto, et al.

    3557 Background: TAS-102 is comprised of an antineoplastic thymidine-based nucleoside analog, trifluridine (FTD), and a thymidine phosphorylase inhibitor, tipiracil hydrochloride. Primary results of the J003-10040030 randomized phase 2 trial demonstrated a significant improvement in overall survival (OS) and progression-free survival (PFS) favoring TAS-102 vs placebo (pbo) in patients (pts) with metastatic colorectal cancer refractory/intolerant to standard therapies (Yoshino T, et al. Lancet Oncology 2012). Neutropenia is the most common TAS-102-associated adverse event and it has been hypothesized to reflect a relatively high FTD concentration in pts. Methods: Study J003 data were analyzed post hoc for correlations between initial onset of Grade 3/4 neutropenia and OS benefit. Results: Of 112 pts given TAS-102, 31 (28%) developed Grade 3/4 neutropenia in treatment cycle 1, 19 (17%) in cycle 2, and 8 (7%) in ≥ cycle 3. Onset of Grade 3/4 neutropenia at cycle 1 and 2 was associated with longer median OS compared to pts without neutropenia as summarized by the hazard ratio (against cycle-matched placebo control groups) and the corresponding median OS differences (see Table). Conclusions: Pts experienced Grade 3/4 neutropenia in cycle 1 and 2 showed a greater OS benefit over pbo. In contrast, pts who did not experience Grade 3/4 neutropenia appear to show no OS benefit. The occurrence of Grade 3/4 neutropenia might become an on-treatment predictive biomarker of TAS-102 and TAS-102 treatment should not be discontinued permanently due to the onset of Grade 3/4 neutropenia. The correlation between efficacy of TAS-102 and onset of neutropenia warrants further analyses. Clinical trial information: 090880.


  • The Nationwide Cancer Genome Screening Project for Gastrointestinal Cancer in Japan (GI-SCREEN): MSI-status and cancer-related genome alterations in advanced colorectal cancer (CRC)—GI-SCREEN 2013-01-CRC sub-study.

    by Takeshi Kajiwara, Kohei Shitara, Tadamichi Denda, Satoshi Yuki, Takao Tamura, Kenta Kawasaki, Eiji Shinozaki, Takako Eguchi Nakajima, Ken Kato, Kiwamu Akagi, et al.

    3573 Background: We initiated a nationwide screening project in Japan to detect rare cancer-related genome alterations in CRC (GI-SCREEN 2013-01-CRC) or non-CRC GI cancer and to facilitate the enrollment of patients (pts) in clinical trials for targeted therapies (Shitara Ket, al ASCO 2015 TPS4134). In this sub-study, we evaluated relationship between MSI status and oncogenic genome alterations as well as clinicopathological features. Methods: Pts with advanced CRC who are or will be treated with systemic chemotherapy were eligible. A total of 36 mutations of KRAS, NRAS, BRAF, PIK3CA in genomic DNA from FFPE tumor specimens were simultaneously analyzed by Luminex (xMAP) technology. Using the MSI Analysis System (Promega) composed of 5 mononucleotide markers, MSI status was analyzed with or without paired DNA from FFPE normal tissue. Results: Among 853 pts enrolled from Feb. 2014 to Jan. 2015, 839 tumor samples have been analyzed for both oncogenic genome alterations and MSI. Mutations in KRAS exon 2, other KRAS or NRAS, BRAF and PIK3CA were detected in 34.0%, 8.0%, 4.6%, and 8.6%, respectively. MSI status was evaluable in 805 pts, of which MSI-H was detected in 15 pts (1.9%). These MSI-H were also detected without normal tissue in this study. Among MSI-H pts, 6 were associated with BRAF V600E mutation, 3 with KRAS exon 2 mutation, and 2 with PIK3CA mutation (overlapping with KRAS exon2). BRAF+MSI-H was associated with older age at presentation and worse OS than non-BRAF+MSI-H (median age, 71.5 vs. 47yrs; median OS, 6.9 vs. 18.1 months).We also found rare germline variants in microsatellite of NR21 and BAT25, and these allele frequencies were 0.33% and 0.25%, respectively. Conclusions: The frequency of MSI-H advanced CRC was 1.9% in Japan. BRAF+MSI-H was associated with worse prognosis. MSI test and multi-oncogenes mutation analysis were feasible without normal tissue, although rare variant of microsatellite markers may affect the decision of MSI status.


  • The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced colorectal cancer.

    by Takeshi Kato, Wataru Okamoto, Tetsuya Hamaguchi, Hiroki Hara, Hiroya Taniguchi, Takuro Mizukami, Tadamichi Denda, Toshikazu Moriwaki, Taito Esaki, Satoshi Yuki, et al.

    3591 Background: We conduct the nationwide cancer genome screening project in Japan from February 2014. Since February 2015, we introduced Next Generation Sequencing method to detect cancer genome alterations in advanced colorectal cancer (aCRC), called as SCRUM-Japan GI-SCREEN 2013-01-CRC. The objective is to evaluate the frequency of cancer genome alterations in aCRC and to identify patients who are candidate for clinical trial for corresponding targeting agents. Methods: This study is ongoing with the participation of 20 major cancer centers. Patients with aCRC who plan to or receive systemic chemotherapy were eligible. Twenty ng of DNA and 10 ng of RNA were extracted from formalin-fixed paraffin embedded (FFPE) tumor samples and were analyzed by the Oncomine Cancer Research Panel (OCP) which allows to detect gene mutation, copy number variant (CNV) and fusions across 143 genes in a CLIA certified CAP accredited laboratory. The detected genomic variant data were classified according to whether genetic driver of cancer, including gain- and loss-of-function or single nucleotide variant based on the Oncomine Knowledgebase. Results: As of October 31st in 2015, a total of 393 aCRC patients were enrolled and 360 samples were available. Out of 360 samples, 345 samples were analyzed and 15 samples are currently under analysis. The sequence with the OCP was successfully performed in 257 tumors (74.5%). The most frequently detected mutations were TP53 (66.9%), APC (56.4%), KRAS (38.9%), PIK3CA (12.1%), and BRAF (10.9%), and CNVs were ERBB2 (3.5%), FLT3 (2.3%), MYC (1.9%), and FGFR1 (1.6%). No gene fusion was detected so far. Patients with BRAF, PIK3CA or FGFR1 mutation were enrolled in early clinical trials. We plan to conduct the investigator initiated studies targeting aCRC patients with ERBB2 amplification and those with BRAF non-V600E mutations. Conclusions: This nationwide screening system is efficient to detect rare mutations in aCRC. This novel knowledge provides an intriguing background to investigate new target approaches in these patients and represents a progress toward more precision medicine. Clinical trial information: UMIN000016343.


    • 1 April 2016
      • Vol. 36  (4) , 1959-66

    Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer.

    by Shuji Arita, Tsuyoshi Shirakawa, Yuzo Matsushita, Hozumi Kumagai Shimokawa, Gen Hirano, Akitaka Makiyama, Yoshihiro Shibata, Shingo Tamura, Taito Esaki, Kenji Mitsugi, et al.

    TAS-102 is an anti-metabolite which demonstrated activity against multidrug-resistant advanced colorectal cancer. Its major toxicities are hematological disorders. Background, TAS-102 efficacy, toxicities and outcomes for patients with multidrug-resistant advanced colorectal cancer from six Institutions of the Kyushu Medical Oncology Group were retrospectively surveyed. Forty-three patients, including fragile patients due to declining performance status and other comorbidities (37%) were analyzed. Efficacy was reflected in an objective overall response of 3%, median progression-free survival of 74 days (2.5 months) and median overall survival of 229 days (7.6 months). The most frequent Common Terminology Criteria for Adverse Events grade 3/4 adverse events were neutropenia (44%), leukopenia (26%) and anemia (23%). Febrile neutropenia was found in 7%. Sub-group analysis demonstrated an improved outcome on treatment with the sequence regorafenib-TAS-102. TAS-102 was safely administered to modestly fragile patients with equivalent efficacy to that for the non-fragile population. Further investigation of sequential treatment using regorafenib and TAS-102 is needed.


  • Open Access

    Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)

    by Mitsukuni Suenaga, Tomohiro Nishina, Nobuyuki Mizunuma, Hisateru Yasui, Takashi Ura, Tadamichi Denda, Junichi Ikeda, Taito Esaki, Hogara Nishisaki, Yoshinao Takano, et al.

    To investigate the efficacy and safety of FOLFIRI plus bevacizumab regimen with irinotecan (180 mg/m2) in patients with advanced or recurrent colorectal cancer who were of the wild-type or heterozygous group for UGT1A1*28 and *6 polymorphisms and discontinued to oxaliplatin-based regimen, prospectively. The study population consisted of patients who had discontinued oxaliplatin-based regimen for any reason. The primary endpoint was the response rate. FOLFIRI and bevacizumab regimen [irinotecan: 180 mg/m2, 5-fluorouracil infusion: 2400 mg/m2, 5-fluorouracil bolus: 400 mg/m2, levofolinate calcium: 200 mg/m2, bevacizumab: 5 mg/kg] was repeated every 2 weeks for up to 24 cycles. Ninety-four patients were enrolled; 93 patients were evaluated on safety, 94 patients on efficacy. The response rate was 10.1% (95% confidence interval (CI): 4.7-18.3%). The median time to treatment failure, progression-free survival, and overall survival were 4.1 months (95% CI: 2.8-4.8 months), 5.4 months (95% CI: 4.1-6.2 months), and 14.5 months (95% CI: 11.8-17.0 months), respectively. The treatment-related death was 1.1%, and the early death ≤30 days after the last study treatment was 1.1%. The incidence of grade 3 or higher adverse events was 60.2% for neutropenia, 23.7% for leukopenia, 9.7% for diarrhea, 6.5% for anorexia, and 5.4% for fatigue. All these adverse events and other adverse events were controllable. FOLFIRI plus bevacizumab regimen with an initial irinotecan dose of 180 mg/m2 exhibited an adequate antitumor effect and was confirmed to be manageable and tolerable in Japanese patients with advanced or recurrent colorectal cancer, who had discontinued oxaliplatin-based regimen. UMIN000001817 .


    • 1 January 2015
      • Vol. 35  (1) , 371-7

    Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan.

    by Gen Hirano, Akitaka Makiyama, Chinatsu Makiyama, Taito Esaki, Hisanobu Oda, Keita Uchino, Masato Komoda, Risa Tanaka, Yuzo Matsushita, Kenji Mitsugi, et al.

    Salvage-line regorafenib monotherapy exhibited a marked survival benefit for metastatic colorectal cancer (mCRC). However, the toxicity of this regimen has resulted in the clinical use of a reduced dose of regorafenib. Thirty-two Japanese mCRC patients (median age=61 years) who had been treated with regorafenib were retrospectively examined. Best objective response rate was 0% and stable disease (SD) was 31%. Median progression-free survival was 81 days and median overall survival was 233 days. Adverse events of any grade were observed in all patients: 17 (53%) patients suffered grade 3 or 4 adverse events including fatigue (13%), anorexia (13%), hand-foot skin reaction (22%) and elevations of alanine aminotransferase/aspartate aminotransferase (19%/16%). One patient with grade 5 liver dysfunction was identified (3%). Twenty-nine (91%) patients required treatment dose reduction or a delay in treatment. The relative dose intensity was 59%. Regorafenib treatments were terminated because of disease progression (59%) or adverse events (34%). Despite a decrease in the intensity of regorafenib treatment, because of severe adverse events, a fairly favorable efficacy was achieved in Japanese patients.